SCHEMBL475130

SCHEMBL475130

Cc1ccc(C(=O)c2cccn2CC=Cc2ccc(COC(C)(C)C(=O)O)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PPARG P37231 10/20 0.56
PPARA Q07869 9/20 0.56
ALDH1A1 P00352 2/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
ALOX12 P18054 1/20 0.36
RECQL P46063 1/20 0.36
KMT2A Q03164 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
GHSR Q92847 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2978389 1.00 PPARG (0.56) PPARGPPARAALDH1A1MEN1LMNA
SCHEMBL475127 1.00 PPARG (0.56) PPARGPPARAALDH1A1MEN1LMNA
SCHEMBL13994554 0.93 PPARG (0.50) PPARGPPARAALDH1A1MEN1LMNA
SCHEMBL13994555 0.91 PPARG (0.49) PPARGPPARAALDH1A1MEN1LMNA
SCHEMBL2978823 0.91 PPARG (0.52) PPARGPPARAALDH1A1NPC1RAB9A
SCHEMBL2353696 0.91 PPARG (0.54) PPARGPPARAALDH1A1MEN1LMNA
SCHEMBL2353699 0.91 PPARG (0.54) PPARGPPARAALDH1A1MEN1LMNA
SCHEMBL2719920 0.91 PPARG (0.52) PPARGPPARAALDH1A1NPC1RAB9A
SCHEMBL2980280 0.91 PPARG (0.52) PPARGPPARAALDH1A1MEN1LMNA
SCHEMBL13994557 0.91 PPARG (0.61) PPARGPPARANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2412705-B1 NOVEL THERAPEUTIC AGENT FOR COGNITIVE IMPAIRMENT DAINIPPON SUMITOMO PHARMA CO (JP) 2014-05-07 EP claimed
EP-2412705-A1 NOVEL THERAPEUTIC AGENT FOR COGNITIVE IMPAIRMENT Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-02-01 EP claimed
US-20120010264-A1 NOVEL MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-01-12 US claimed
US-20110212892-A1 AGENT FOR TREATMENT OF DIABETES DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-01 US claimed
EP-2351563-A1 AGENT FOR TREATMENT OF DIABETES Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-08-03 EP claimed
EP-2412705-B1 NOVEL THERAPEUTIC AGENT FOR COGNITIVE IMPAIRMENT DAINIPPON SUMITOMO PHARMA CO (JP) 2014-05-07 EP disclosed
EP-1647546-B1 NOVEL HETEROARYL DERIVATIVE DAINIPPON SUMITOMO PHARMA CO (JP) 2012-05-02 EP disclosed
CN-102365269-A Novel drugs for the treatment of cognitive impairment DAINIPPON SUMITOMO PHARMA CO 2012-02-29 CN disclosed
EP-2412705-A1 NOVEL THERAPEUTIC AGENT FOR COGNITIVE IMPAIRMENT Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-02-01 EP disclosed
EP-2412705-A1 NOVEL THERAPEUTIC AGENT FOR COGNITIVE IMPAIRMENT Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-02-01 EP disclosed
US-20120010264-A1 NOVEL MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-01-12 US disclosed
US-20120010264-A1 NOVEL MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-01-12 US disclosed
US-7781479-B2 Heteroaryl derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-08-24 US disclosed
WO-2010050422-A1 AGENT FOR TREATMENT OF DIABETES 大日本住友製薬株式会社 (JP) 2010-05-06 WO disclosed
US-20080306275-A1 NOVEL HETEROARYL DERIVATIVE DANIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-12-11 US disclosed
US-7425642-B2 Heteroaryl derivative DAINIPPON SUMITOMO PHARMA CO. ,LTD. (JP) 2008-09-16 US disclosed
US-20080167306-A1 Novel Heteroaryl Derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-07-10 US disclosed
EP-1837329-A1 NOVEL HETEROARYL DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2007-09-26 EP disclosed
US-20060194857-A1 Novel heteroaryl derivative DAINIPPON SUMITOMO PHARMA CO. LTD. (JP) 2006-08-31 US disclosed
EP-1647546-A1 NOVEL HETEROARYL DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-04-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212892-A1 AGENT FOR TREATMENT OF DIABETES SLC5A1, GLP1R, SLC5A2 PPARG 62/4885PPARA 16/4885ALDH1A1 291/4885
US-20060194857-A1 Novel heteroaryl derivative NR0B1, UGT1A10, NR0B2 PPARG 282/4885PPARA 411/4885ALDH1A1 552/4885
US-20120010264-A1 NOVEL MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT PSEN2, PSEN1, GRIK5 PPARG 291/4885PPARA 256/4885ALDH1A1 2642/4885
US-20080167306-A1 Novel Heteroaryl Derivative GPR119, SLC2A4, SLC5A2 PPARG 498/4885PPARA 561/4885ALDH1A1 699/4885
US-20080306275-A1 NOVEL HETEROARYL DERIVATIVE NR0B1, UGT1A10, NR0B2 PPARG 282/4885PPARA 411/4885ALDH1A1 552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.